← 返回

免疫检查点抑制剂与 CAR-T 细胞治疗的心脏并发症

英文原题:Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy.

查看英文原题

Cardiac Complications of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy.

PubMed 2024/08/30(内容时间) Cardiol Clin Q3 · IF 1.4(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

免疫检查点抑制剂和CAR-T 细胞疗法彻底改变了癌症治疗,但可能通过免疫相关不良事件导致危及生命的心血管毒性。心肌炎是免疫检查点抑制剂最常见且可能致命的毒性。T细胞疗法可能导致细胞因子释放综合征(CRS)。诊断免疫检查点抑制剂相关心肌炎需要采用多模态方法,包括生物标志物、影像学和心内膜心肌活检;CRS则表现为类似分布性休克的临床综合征。管理措施包括停用致病治疗,对免疫检查点抑制剂相关心肌炎使用皮质类固醇进行免疫抑制,并对CRS使用白细胞介素6拮抗剂。肿瘤科医生与心脏科医生协作,对于早期识别和及时治疗至关重要。

展开英文摘要原文

Immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy have revolutionized cancer treatment but can cause life-threatening cardiovascular toxicities through immune-related adverse events. Myocarditis is the most common and potentially fatal toxicity with immune checkpoint inhibitors. T-cell therapies can potentially lead to cytokine release syndrome.

Diagnosis of ICI-myocarditis requires a multimodal approach, including biomarkers, imaging, and endomyocardial biopsy, while CRS is characterized by a clinical syndrome resembling distributive shock. Management involves discontinuing the offending therapy, immunosuppression with corticosteroids for ICI-myocarditis, and interleukin-6 antagonists for CRS. Collaboration between oncologists and cardiologists is crucial for early recognition and prompt treatment.

论文信息

作者
Makwana B、Malode A、Khadke S、Patel V、Shah R、Patel M、Parikh A、Dani SS
第一作者单位
Division of Cardiology, Department of Internal Medicine, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805, USA.United States
通讯作者单位
Division of Cardiology, Department of Internal Medicine, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805, USA; Department of Medicine (Research), Cardio-Oncology Program, Lahey Hospital and Medical Center, 41 Mall Road, Burlington, MA 01805, USA. Electronic address: Sarju.Ganatra@Lahey.org.United States
文献类型
综述
期刊
Cardiology clinics2025 Feb
原文标识
PubMed 39551556 · DOI 10.1016/j.ccl.2024.07.001